The therapeutic community is abuzz with anticipation surrounding retatrutide fda retatrutide, a new dual GIP and GLP-1 receptor that’s showing significant potential in clinical trials for addressing obesity. Unlike some available weight loss solutions, retatrutide appears to provide a significant substantial loss in body weight and benefit metabo